

US Patent Office grants Stimunity's patent that covers its cGAMP-VLP technology

Paris, May 24 – Stimunity, the Paris-based cancer immunotherapy company focused on STING, is pleased to announce that the US Patent Office (USPTO) has granted its main patent that covers any VLPs that encapsulate cGAMP.

Stimunity's core technology cGAMP-VLP which activates the innate immune system and induces a systemic T cell response against tumor cells, is protected by a family of patents that have been exclusively licensed from Institut Curie and Institut National de la Santé et de la Recherche Médicale (INSERM). The US patent, [US2016/074507](#), entitled "Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response" filed in September 2014, covers any virus-like particle comprising a lipoprotein envelope including a viral fusogenic glycoprotein and that contains cGAMP inside. The patent also covers all the biological methods to produce these particles.

"This is a very good news for the company, as this patent secures our R&D investments to move forward our cGAMP-VLP program into the clinic. Sometimes, US patent proceeding could be long and expensive, so it is a great news that the patent was granted rapidly. This also shows that our approach is well differentiated from any other state-of-the-art technologies" said Sylvain Carlioz, CEO.

Intellectual Property constitutes a key asset of the company. It is at the heart of its R&D strategy and provides a long-term protection for Stimunity's products.

About Stimunity



Stimunity is an early-stage research and development company focused on the development of STING agonists in cancer. The technology, licensed from Institut Curie, Inserm, and University of Oxford, is based on a unique biologic approach which combines the endogenous STING activator encapsulated in a Virus-Like Particle (VLP). Stimunity's drug is best-in-class, and activates the innate immune system, enhances T-cell response against tumor cells, with a low immunogenicity. Stimunity is incubated at Paris Biotech Santé, and was laureate of the French National Startup Competition I-Lab 2017, and Biovision Catalyzer Price.

More information at <http://stimunity.com> or contact@stimunity.com.